QSAM News and Press, QSAM Biosciences Inc From 04/26/23

2023-04-26 08:56:34 ET QSAM Biosciences ( OTCQB:QSAM ) announced the reception of a second patent from the European Patent Office. The patent safeguards the use of "lower specific activity" Samarium-153 when treating bone cancer in children and adults. This new patent in Europe co...

Austin, TX, April 26, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of cancer and other diseases, announced today that the European Pat...

QSAM Biosciences (OTCQB: QSAM) , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, has announced enrollment for its phase 1 study of CycloSam(R)   in the t...

Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and other diseases and conditions, today announces t...

2023-03-08 09:30:07 ET QSAM Biosciences ( OTCQB:QSAM ) said on Wednesday the U.S. Food & Drug Administration (FDA) had cleared its clinical trial protocol to increase the maximum age of participants to 75 years old from the prior age limitation of 65, in a phase 1 study te...

Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases and conditions, today announces...

QSAM Biosciences (OTCQB: QSAM) , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, is spotlighted in a new opportunity research report released by Goldman Small...

BALTIMORE, MD / ACCESSWIRE / March 1, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on clinical stage biotech QSAM Biosciences, Inc. (OTCQB:QSAM), a developer of ne...

QSAM Biosciences (OTCQB: QSAM) , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, has completed enrollment in its first participant grouping, or cohort, for it...

Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases and conditions, today announces ...